What question did this study set out to answer?

This study aims to explore how baseline immune profiles influence responses to bispecific antibodies in patients with relapsed/refractory multiple myeloma.

April 19, 2026HaematologicaOpen Access

P56 | Baseline Immune Profile Predicts Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Real-World Monocentric Exploratory Analysis

View Full Paper

Ask AI

Bookmark

Authors

RPR.D. PepaFederico II University Hospital ALA LeoneFederico II University Hospital LEL. EspositoFederico II University Hospital

Discussion

Member takes

Implication

Monocentric exploratory analysis shows immune profiling impacts bispecific antibody outcomes in relapsed myeloma, indicating potential treatment strategies.

Key Points

This study aims to explore how baseline immune profiles influence responses to bispecific antibodies in patients with relapsed/refractory multiple myeloma.
Analyzed relapsed/refractory multiple myeloma patients treated with bispecific antibodies at a single center.
Collected peripheral blood samples at multiple timepoints to assess immune parameters.
Measured absolute lymphocyte count, CD8+ T-cell percentage, and plasma IL-6 levels as biomarkers.
Categorized patients based on response using IMWG classification and evaluated treatment sequencing.
Basal CD8+ T-cell percentage was significantly higher in patients achieving complete response compared to those with partial or stable disease (p=0.03).
Higher baseline IL-6 levels correlated with lower response rates (p=0.02).
Patients with favorable immune profiles (high CD8+, low IL-6) maintained better responses.
Prior BCMA exposure was linked to reduced CD8+ levels and worse outcomes (p=0.03).

Cite This Study

Pepa et al. (2026) studied this question.

synapsesocial.com/papers/69e4702d010ef96374d8d5fb https://doi.org/10.3324/haematol.2026.s2.14097

View Full Paper

Ask AI

Bookmark

Implication

Monocentric exploratory analysis shows immune profiling impacts bispecific antibody outcomes in relapsed myeloma, indicating potential treatment strategies.

P56 | Baseline Immune Profile Predicts Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Real-World Monocentric Exploratory Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

P56 | Baseline Immune Profile Predicts Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Real-World Monocentric Exploratory Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider